High Precision RT For Soft-Tissue Sarcoma

Status Completed

Clinical Trial Summary

This research study aims at defining 1) how retroperitoneal sarcomas change over the course of radiotherapy and 2) how radiotherapy affects your well-being. While the investigators know that radiotherapy before surgery is safe and effective, the amount of tumor motion and size change during radiotherapy is unknown. There is also very little information that describes the side-effects of radiotherapy in the treatment of this disease.

Clinical Trial Description

Soft-tissue sarcomas (STS) that arise from the retroperitoneum are rare malignancies that are anatomical located deep within the abdominal area and thus pose challenges to surgical and radiotherapeutic management of the patient. As a result, the local control and overall survival for patients with retroperitoneal sarcomas (RPS) are worse than STS from the extremities. Current treatment strategy involves pre-operative radiotherapy followed by surgery. Use of intensity-modulated radiotherapy (IMRT) in RPS had allowed for more conformal treatments with the aim of sparing normal tissues from high doses of irradiation. Yet the accuracy and coverage of IMRT depend highly on target motion, and little is known about the motion of RPS during the course of radiotherapy. As well, RPS are commonly in close proximity to sensitive organs for which the long-term toxicity and effect on quality of life secondary to radiation is unknown. The current study seeks to evaluate the extent of tumor motion during radiotherapy and the impact of radiotherapy to patient toxicity and quality of life. At the conclusion of this study, our results will hopefully identify the optimum PTV, the importance of different normal tissues and their dose-volume constraints, the role of image guidance, and the potential for dose escalation in the treatment of RPS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01389050
Study type	Interventional
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	Phase 2
Start date	June 1, 2011
Completion date	January 6, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03007771` - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia	Phase 1
Recruiting	`NCT02630368` - A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)	Phase 1/Phase 2
Completed	`NCT01438554` - Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Phase 1
Active, not recruiting	`NCT03602833` - Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma	Phase 1/Phase 2
Recruiting	`NCT03475953` - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03242382` - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.	Phase 2
Recruiting	`NCT04181970` - Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
Recruiting	`NCT03096912` - A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma	Phase 2
Completed	`NCT02787642` - A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma	Phase 1
Terminated	`NCT02987959` - Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas	Phase 2
Recruiting	`NCT03175718` - INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy Patients	N/A
Recruiting	`NCT05741944` - The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients	N/A
Active, not recruiting	`NCT03016819` - Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)	Phase 3